argenx SE (ARGX)
Company Description
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB.
The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH.
It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Country | NL |
IPO Date | May 18, 2017 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 1,599 |
CEO | Timothy Van Hauwermeiren EMBA, M.Sc. |
Contact Details
Address: Laarderhoogtweg 25 Amsterdam, NL | |
Website | https://www.argenx.com |
Stock Details
Ticker Symbol | ARGX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001697862 |
CUSIP Number | 04016X101 |
ISIN Number | US04016X1019 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Timothy Van Hauwermeiren EMBA, M.Sc. | Co-Founder, Chief Executive Officer & Executive Director |
Karen Massey | Chief Operating Officer |
Karl Gubitz | Chief Financial Officer |
Andria Wilk | Global Head of Quality |
Arjen Lemmen M.Sc. | Vice President of Corporate Development & Strategy |
Beth DelGiacco | Vice President and Global Head of Corporate Communications & Investor Relations |
Dr. Luc Truyen | Chief Medical Officer |
Dr. Peter Ulrichts | Chief Scientific Officer |
Filip Borgions | Vice President & Global Head of Technical Operations |
Malini Moorthy | General Counsel |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 20, 2025 | 20-F | Filing |
Mar 20, 2025 | 6-K | Filing |
Mar 07, 2025 | 6-K | Filing |
Feb 27, 2025 | 6-K | Filing |
Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 13, 2025 | 6-K | Filing |
Dec 27, 2024 | 6-K | Filing |
Nov 20, 2024 | 6-K | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |